PainReform Ltd. (PRFX)

NASDAQ: PRFX · Real-Time Price · USD

1.930

+0.050 (2.66%)

At close: May 30, 2025, 4:00 PM

1.910

-0.020 (-1.04%)

After-hours: May 30, 2025, 5:41 PM EDT

PainReform Employees

As of December 31, 2024, PainReform had 6 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 1 or -14.29% compared to the previous year.

Employees

6

Change (1Y)

-1

Growth (1Y)

-14.29%

Revenue / Employee

n/a

Profits / Employee

-$2,431,333

Market Cap

3.89M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	6	-1	-14.29%
Dec 31, 2023	7	1	16.67%
Dec 31, 2022	6	2	50.00%
Dec 31, 2021	4	2	100.00%
Dec 31, 2020	2	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

PRFX News

3 days ago - Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales - PRNewsWire
23 days ago - PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects - GlobeNewsWire
7 weeks ago - PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market - GlobeNewsWire
7 weeks ago - PainReform Provides Year-End Business Update - GlobeNewsWire
3 months ago - PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics - GlobeNewsWire
3 months ago - PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity - GlobeNewsWire
5 months ago - PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110 - GlobeNewsWire
6 months ago - PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial - GlobeNewsWire